Experience with the use of a first‐line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database

Abstract

These real-life data provide an insight into clinical practice in Asia and the Pacific region. d4T/3TC/NVP is maintained longer than other first-line regimens and change is mainly as a result of adverse effects rather than clinical failure. There is a need to develop affordable second-line antiretroviral treatment options for patients with HIV infection in developing countries.